最新消息
News
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026漢康生技全球臨床佈局加速 2026年第一季將於多場國際年會發表口頭及壁報論文
HanchorBio announced a robust schedule of scientific presentations at major international oncology congresses throughout Q1 2026. The selection of multiple abstracts, including four high-profile oral presentations, underscores the clinical maturity and global scientific recognition of HanchorBio’s proprietary pipeline.
2 月 05, 2026
Read more
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation漢康生技於2026 ASCO GI消化道腫瘤大會發表 HCB101 聯合標準治療在二線胃癌之臨床數據
HanchorBio Reports High Objective Response Rate with HC […]
1 月 09, 2026
Read more
HanchorBio to Present Encouraging Early Clinical Activity of HCB101 in Combination with Standard-of-Care Therapy for Second-Line Gastric Cancer at ASCO GI 2026漢康生技將於2026 ASCO消化道腫瘤大會發布 HCB101 聯合標準治療在二線胃癌中的早期臨床數據
HanchorBio to Present Encouraging Early Clinical Activi […]
1 月 05, 2026
Read more
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025漢康生技HCB101獲選2025年ESMO免疫腫瘤學大會口頭報告
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 12, 2025
Read more
【Meeting Preview】HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 10, 2025
Read more
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 漢康生技於 2025 年美國血液學會（ASH）年會發表 HCB101 單藥治療人體試驗結果
HanchorBio Presents First-in-Human Data of HCB101 Monot […]
12 月 09, 2025
Read more
【Meeting Preview】HanchorBio Presents First-in-Human Phase 1 Data of HCB101 at the 67th American Society of Hematology (ASH) Annual Meeting 漢康生技於第 67 屆美國血液學會（ASH）年會公布 HCB101 I 期臨床數據
HanchorBio Presents First-in-Human Phase 1 Data of HCB1 […]
12 月 03, 2025
Read more
HanchorBio Strengthens R&D Strategy with Productive SAB Meeting Focusing on Promising HCB101 Data and Pipeline Innovation
HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.
10 月 08, 2025
Read more
HanchorBio Strengthens R&D Strategy with Productive SAB Meeting Focusing on Promising HCB101 Data and Pipeline Innovation 漢康生技強化研發策略 聚焦HCB101臨床亮眼數據與創新管線的專家諮詢委員會（SAB）會議圓滿舉行
HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.
10 月 08, 2025
Read more
HanchorBio Invited to Present at the CBA 27th Annual Conference as the Sole Innovative Drug Company Representing Taiwan
Showcase the Broad Therapeutic Potential of HCB101 in Tumor Immunotherapy
*As the only innovative drug company from Taiwan invited to this year’s CBA Annual Conference, HanchorBio took the international stage to present its AI-assisted Structural Engineering on SIRP-alfa fusion biologic for enhancing Safety and Efficacy, marking an important milestone for Taiwan’s biotech industry.”
*This recognition not only strengthens Taiwan’s position in global AI-assisted drug development, but also opens new opportunities for cross-border licensing and collaboration.
10 月 02, 2025
Read more